55个品种纳入，第十一批国家药品集采报量启动

Core Viewpoint - The article discusses the transformation of China's drug procurement policy from a "low-price only" approach to a "quality first" strategy, marking a significant reform in the pharmaceutical industry that balances efficiency and clinical needs [1][2][5]. Group 1: Changes in Procurement Rules - The 11th batch of national drug centralized procurement involves 55 varieties, with a new rule allowing medical institutions to report demand by brand name instead of only by generic name [1][2]. - A reporting threshold of 80% of the average usage over the past two years has been established, requiring institutions to report no less than this amount [1][7]. - Institutions can provide written explanations for significant decreases in expected usage due to clinical demand changes [1][7]. Group 2: Quality Control and Market Dynamics - The new procurement rules emphasize quality control, requiring companies to have at least two years of production experience and compliance with quality management standards [7][9]. - The principle of "anti-involution" aims to prevent excessive price competition, encouraging companies to focus on quality and reasonable profits [9][10]. - The procurement process is designed to stabilize market expectations, allowing companies to better manage production and inventory [10]. Group 3: Impact on the Pharmaceutical Industry - The changes in procurement rules are expected to reshape the industry supply chain logic, with a focus on maintaining clinical stability and quality assurance [5][11]. - The procurement process will allow for flexible adjustments based on seasonal demand and specific needs, particularly for pediatric medications [11][12]. - The article highlights the potential for further price reductions in the market, benefiting patients while also posing challenges for companies facing increased competition [12][13].